Diampark Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$546K
- Investors
-
2
Diampark General Information
Description
Developer of digital assessment software designed to facilitate daily management and clinical monitoring for individuals with neurodegenerative conditions. The company offers a digital medical device that utilizes smartphone sensors and smartwatch integration to capture motor and vocal biomarkers, enabling patients to track disease progression and share objective data with healthcare professionals for optimized care.
Contact Information
Website
www.diampark.ioCorporate Office
- Siege Social
- Paris
- France
Corporate Office
- Siege Social
- Paris
- France
Diampark Timeline
Diampark Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC | 03-Jan-2024 | $546K | Completed | Generating Revenue | ||
| 4. Accelerator/Incubator | 01-Jan-2024 | Completed | Generating Revenue | |||
| 3. Seed Round | 12-Feb-2023 | Completed | Pre-Clinical Trials | |||
| 2. Angel (individual) | 07-Mar-2022 | $201K | $201K | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | 01-Jul-2021 | Completed | Pre-Clinical Trials |
Diampark Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 6,479 | $1.092934 | $30.16 | $30.16 | 1x | $30.16 | 9.4% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Diampark Patents
Diampark Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4491112-A1 | Method and device for determining a recommended dose of a drug for treating parkinson's disease | Inactive | 13-Jul-2023 | ||
| EP-4491111-A1 | Method and device for monitoring an individual suffering from a neurodegenerative disease | Inactive | 13-Jul-2023 | ||
| WO-2024146947-A1 | Device for determining the recommended dose of a drug for the treatment of parkinson's disease | Inactive | 05-Jan-2023 | ||
| WO-2024146940-A1 | Method and device for monitoring an individual with a neurodegenerative disease | Inactive | 05-Jan-2023 | ||
| WO-2024115853-A1 | Method for determining a patient's sensitivity to a drug prescribed for treating a neurodegenerative disease | Inactive | 29-Nov-2022 | G16H50/20 |
Diampark Signals
Diampark Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Servier | Corporation | |||
| iPEPS-ICM | Accelerator/Incubator |
Diampark FAQs
-
When was Diampark founded?
Diampark was founded in 2020.
-
Where is Diampark headquartered?
Diampark is headquartered in Paris, France.
-
What is the size of Diampark?
Diampark has 16 total employees.
-
What industry is Diampark in?
Diampark’s primary industry is Other Healthcare Technology Systems.
-
Is Diampark a private or public company?
Diampark is a Private company.
-
What is the current valuation of Diampark?
The current valuation of Diampark is .
-
What is Diampark’s current revenue?
The current revenue for Diampark is .
-
How much funding has Diampark raised over time?
Diampark has raised $1.11M.
-
Who are Diampark’s investors?
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process